Compare LMFA & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMFA | KALA |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.0M |
| IPO Year | 2015 | 2017 |
| Metric | LMFA | KALA |
|---|---|---|
| Price | $0.42 | $0.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $31.50 |
| AVG Volume (30 Days) | 496.2K | ★ 2.2M |
| Earning Date | 11-14-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,567,508.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $0.51 |
| 52 Week High | $5.14 | $20.60 |
| Indicator | LMFA | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 41.28 |
| Support Level | $0.40 | $0.58 |
| Resistance Level | $0.46 | $0.71 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.44 | 14.22 |
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.